Recombinant Mouse CD72 protein (rFc Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg2708
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Mouse CD72 protein Arg117-Asn354 (Accession# P21855) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 12517 |
| Accession | P21855 |
| PredictedSize | 54.9 kDa |
| SDS-PAGE | 55-65 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CD72 is a type II transmembrane co-receptor expressed on B cells, playing a crucial role in regulating B cell activation and immune responses. It contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that negatively regulate B cell receptor (BCR) signaling by recruiting the tyrosine phosphatase SHP-1. CD72 also interacts with CD5 on T cells, supporting its role in T-dependent B cell activation. In autoimmune diseases like systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome, CD72 expression is dysregulated, with increased levels of soluble CD72 correlating with disease activity. Additionally, CD72-deficient mice exhibit hyper-responsive B cells, highlighting its importance in maintaining immune homeostasis. These findings suggest that CD72 is a potential therapeutic target for modulating B cell activity in autoimmune and inflammatory conditions.
References:
1. Parnes, J R, and C Pan. Immunological reviews vol. 176 (2000): 75-85. 2. Tsubata, Takeshi. Immune network vol. 19,1 (2019): e1. 3. Temple, William C et al. Journal for immunotherapy of cancer vol. 11,11 (2023): e006985. 4. Eiza, Nasren et al. Frontiers in immunology vol. 15 (2024): 1367120.